Skip to main content

Table 3 Estimation of PAR, ASP and DIPH in Excedrin® PM Headache caplets by the proposed spectrophotometric methods and application of standard addition technique

From: Eco-friendly resolution of spectrally overlapping signals of a combined triple-action over-the-counter pharmaceutical formulation for symptomatic management of COVID-19 pandemic: application to content uniformity testing

Drug

Excedrin® PM Headache caplets (BN: 46172679) (Each caplet labelled to contain 250 mg PAR, 250 mg ASP & 38 mg DIPH as citrate salt)

Standard Addition Technique

%Found ± SDa

Claimed (μg/mL)

Pure added (μg/mL)

%Recovery of the pure addedb

PAR

100.55 ± 1.320

10

5.0

101.08

10.0

100.64

20.0

99.84

Mean ± SD

100.52 ± 0.631

ASP

100.47 ± 1.507

10

5.0

98.76

10.0

98.6

20.0

99.99

Mean ± SD

99.12 ± 0.760

DIPH

100.16 ± 1.225

1.5

1.0

98.25

1.5

100.58

3.0

100.00

Mean ± SD

99.61 ± 1.217

  1. aAverage of five determinations
  2. bAverage of three experiments